| Features: |
| Zerumbone is a sesquiterpene α,β-unsaturated carbonyl compound derived primarily from Zingiber zerumbet (shampoo ginger). It is one of the most intensively studied dietary terpenoids for anticancer activity, with a strong and internally consistent mechanism-of-action profile across multiple cancer types.
Zerumbone induces intrinsic (mitochondrial) apoptosis via: -↑ ROS generation in cancer cells -Loss of mitochondrial membrane potential -↑ Bax / ↓ Bcl-2 and Bcl-xL -Cytochrome c release -Caspase-9 → caspase-3 activation Zerumbone is a potent NF-κB inhibitor Anti-angiogenic and anti-metastatic effects -Observed actions include: -↓ VEGF and HIF-1α -↓ MMP-2 / MMP-9 -Suppression of EMT markers (N-cadherin, vimentin) -Reduced migration and invasion Zerumbone is a redox-bifunctional agent: In cancer cells: -↑ ROS beyond survival threshold -Triggers mitochondrial collapse In normal cells: -Activates Nrf2 -Induces phase II detox enzymes (HO-1, NQO1, GST) This differential redox response explains selective toxicity. Bioavailability is limited |
| Source: HalifaxProj (inactivate) |
| Type: |
| β-catenin and ZEB1 are two important proteins that play significant roles in cancer biology, particularly in the processes of cell adhesion, epithelial-mesenchymal transition (EMT), and tumor progression. β-catenin is a key component of the Wnt signaling pathway, which is crucial for cell proliferation, differentiation, and survival. It also plays a role in cell-cell adhesion by linking cadherins to the actin cytoskeleton. Role in Cancer: ZEB1 is often upregulated in cancer and is associated with increased invasiveness and metastasis. It can repress epithelial markers (like E-cadherin) and promote mesenchymal markers (like N-cadherin and vimentin), facilitating the transition to a more aggressive cancer phenotype. (MMP)-2 and MMP-9, which are the down-stream targets of β-catenin and play a crucial role in cancer cell metastasis. |
| 4888- | ZER, | 5-FU, | Modulation of the tumor microenvironment by zerumbone and 5-fluorouracil in colorectal cancer by target in cancer-associated fibroblasts |
| - | in-vitro, | CRC, | CT26 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:384 Target#:342 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid